



ArQule, Inc.
Investor Relations Department
One Wall Street
Burlington, MA 01803
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ARQL

Last Trade:	1.20
Trade Time:	4:00 PM ET May 22, 2017
Change:	-0.06 (-4.762%)
Day Range	1.16 - 1.28
52-Week Range	0.92 - 2.17
Volume	405,295


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need. ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy.

ArQule i... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

May 18, 2017

[ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association \(EHA\)](#)

May 17, 2017

[ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

May 3, 2017

[ArQule Reports First Quarter 2017 Financial Results](#)

Apr 26, 2017

[ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531](#)

Apr 19, 2017

[ArQule To Report First Quarter 2017 Financial Results On May 3, 2017](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 13, 2017

[Proxy Statement \(DEF 14A\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 3, 2016

[Quarterly Report \(10-Q\)](#)